Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104740 | 0.92 | TLR8 (0.74) | TLR8TLR7 | |
| SCHEMBL12619304 | 0.91 | TLR8 (0.73) | TLR8TLR7 | |
| SCHEMBL10325097 | 0.86 | TLR8 (0.63) | TLR8TLR7 | |
| SCHEMBL15625323 | 0.86 | TLR8 (0.58) | TLR8TLR7 | |
| SCHEMBL22771214 | 0.85 | TLR8 (0.60) | TLR8TLR7 | |
| SCHEMBL8191084 | 0.85 | TLR8 (0.60) | TLR8TLR7 | |
| SCHEMBL1901276 | 0.84 | TLR8 (0.53) | TLR8TLR7 | |
| SCHEMBL10325134 | 0.84 | TLR8 (0.53) | TLR8TLR7 | |
| SCHEMBL19642416 | 0.84 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL1656313 | 0.83 | TLR8 (0.69) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20200405813-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA, INC. | 2020-12-31 | — | — | US | disclosed |
| WO-2020252015-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | TLR8 87/4885TLR7 210/4885 |
| US-20200405813-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | TLR8 80/4885TLR7 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.